CYTEK BIOSCIENCES INC (CTKB)
US23285D1090 - Common Stock
Overall CTKB gets a fundamental rating of 5 out of 10. We evaluated CTKB against 57 industry peers in the Life Sciences Tools & Services industry. CTKB has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CTKB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CTKB had negative earnings in the past year.
In the past year CTKB had a positive cash flow from operations.
In multiple years CTKB reported negative net income over the last 5 years.
In multiple years CTKB reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of CTKB (-3.63%) is better than 63.16% of its industry peers.
CTKB's Return On Equity of -4.51% is fine compared to the rest of the industry. CTKB outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.63% | ||
| ROE | -4.51% | ||
| ROIC | N/A |
ROA(3y)-0.65%
ROA(5y)-4.87%
ROE(3y)-0.83%
ROE(5y)-10.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 54.97%, CTKB is doing good in the industry, outperforming 71.93% of the companies in the same industry.
CTKB's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CTKB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.58%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTKB has less shares outstanding
CTKB has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.50 indicates that CTKB is not in any danger for bankruptcy at the moment.
CTKB's Altman-Z score of 6.50 is amongst the best of the industry. CTKB outperforms 80.70% of its industry peers.
The Debt to FCF ratio of CTKB is 0.31, which is an excellent value as it means it would take CTKB, only 0.31 years of fcf income to pay off all of its debts.
CTKB has a better Debt to FCF ratio (0.31) than 92.98% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CTKB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CTKB is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.31 | ||
| Altman-Z | 6.5 |
ROIC/WACCN/A
WACC10.87%
2.3 Liquidity
A Current Ratio of 7.33 indicates that CTKB has no problem at all paying its short term obligations.
The Current ratio of CTKB (7.33) is better than 82.46% of its industry peers.
A Quick Ratio of 6.38 indicates that CTKB has no problem at all paying its short term obligations.
CTKB has a better Quick ratio (6.38) than 82.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.33 | ||
| Quick Ratio | 6.38 |
3. Growth
3.1 Past
CTKB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -215.94%.
The Revenue has grown by 9.88% in the past year. This is quite good.
The Revenue has been growing by 27.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-215.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1100%
Revenue 1Y (TTM)9.88%
Revenue growth 3Y27.65%
Revenue growth 5YN/A
Sales Q2Q%7.29%
3.2 Future
CTKB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.95% yearly.
Based on estimates for the next years, CTKB will show a quite strong growth in Revenue. The Revenue will grow by 10.02% on average per year.
EPS Next Y-224.9%
EPS Next 2Y9.88%
EPS Next 3Y20.95%
EPS Next 5YN/A
Revenue Next Year7.22%
Revenue Next 2Y9.17%
Revenue Next 3Y10.02%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CTKB. In the last year negative earnings were reported.
CTKB is valuated quite expensively with a Price/Forward Earnings ratio of 114.77.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CTKB is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.73, CTKB is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 114.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CTKB is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 82.11 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CTKB's earnings are expected to grow with 20.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.88%
EPS Next 3Y20.95%
5. Dividend
5.1 Amount
No dividends for CTKB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTEK BIOSCIENCES INC
NASDAQ:CTKB (1/6/2025, 4:30:01 PM)
After market: 6.79 0 (0%)6.79
-0.04 (-0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners58.68%
Inst Owner Change-0.02%
Ins Owners8.62%
Ins Owner Change1.06%
Market Cap874.62M
Analysts80
Price Target8.52 (25.48%)
Short Float %3.15%
Short Ratio5.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-91.99%
Min EPS beat(2)-161.44%
Max EPS beat(2)-22.55%
EPS beat(4)1
Avg EPS beat(4)197.6%
Min EPS beat(4)-161.44%
Max EPS beat(4)1077.65%
EPS beat(8)3
Avg EPS beat(8)93.15%
EPS beat(12)6
Avg EPS beat(12)93.28%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-7.72%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-5.27%
Min Revenue beat(4)-15.17%
Max Revenue beat(4)0.9%
Revenue beat(8)3
Avg Revenue beat(8)-6.42%
Revenue beat(12)6
Avg Revenue beat(12)-3.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.6%
PT rev (3m)-4.02%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)-500%
EPS NY rev (1m)0%
EPS NY rev (3m)28.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 114.77 | ||
| P/S | 4.42 | ||
| P/FCF | 82.11 | ||
| P/OCF | 56.68 | ||
| P/B | 2.25 | ||
| P/tB | 2.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.08
EYN/A
EPS(NY)0.06
Fwd EY0.87%
FCF(TTM)0.08
FCFY1.22%
OCF(TTM)0.12
OCFY1.76%
SpS1.53
BVpS3.02
TBVpS2.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.63% | ||
| ROE | -4.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.97% | ||
| FCFM | 5.39% |
ROA(3y)-0.65%
ROA(5y)-4.87%
ROE(3y)-0.83%
ROE(5y)-10.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.58%
GM growth 5YN/A
F-Score5
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.31 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 69.23% | ||
| Cap/Sales | 2.42% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.33 | ||
| Quick Ratio | 6.38 | ||
| Altman-Z | 6.5 |
F-Score5
WACC10.87%
ROIC/WACCN/A
Cap/Depr(3y)275.94%
Cap/Depr(5y)279.81%
Cap/Sales(3y)3.98%
Cap/Sales(5y)3.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-215.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1100%
EPS Next Y-224.9%
EPS Next 2Y9.88%
EPS Next 3Y20.95%
EPS Next 5YN/A
Revenue 1Y (TTM)9.88%
Revenue growth 3Y27.65%
Revenue growth 5YN/A
Sales Q2Q%7.29%
Revenue Next Year7.22%
Revenue Next 2Y9.17%
Revenue Next 3Y10.02%
Revenue Next 5YN/A
EBIT growth 1Y-30.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year198.31%
EBIT Next 3Y57.35%
EBIT Next 5YN/A
FCF growth 1Y218.09%
FCF growth 3Y-67.81%
FCF growth 5YN/A
OCF growth 1Y458.05%
OCF growth 3Y-29.64%
OCF growth 5YN/A